Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986. Since then, the pharmaceutical industry has sought opportunities to leverage antibody technology as therapeutic agents to treat human disease. PK/PD modeling has been a useful technique to integrate data generated from diverse test platforms in mechanism framework.
This webinar will focus on :
- Introduction to Antibody Drug Conjugate (ADC)
- Development of mechanistic PK/PD model for preclinical-to-clinical translation of ADCs
- Application of PK/PD modeling to understand the disposition of ADCs and guide the development of ADC
A live Q&A with the audience will follow the presentation.
Dhaval Shah,PhD, MS Pharmaceutics, Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York
Dr. Shah worked as a Prinicpal Scientist at Pfizer prior to his current position as Assistant Professor at UB, The State University of New York, his alma mater. Dr. Shah’s research interests include discovery and development of novel biological drugs like ADCs for the treatment of cancer, obesity. His work integrates the principles of PK/PD and mathematical modeling to quantify the efficacy and toxicity of drugs, which in turn provides a predictive systems framework for successful preclinical-to-clinical translation of drugs.Message Presenter
Who Should Attend?
Managers,Group Head,Laboratory Heads,Scientists,Regulatory Managers,Scientist in the following departments:
- Antibody-Drug Conjugates
- Pre-Clinical/Clinical Development
- Target Validation
- Protein/Antibody Engineering
- CMC & Regulatory